Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Residual Anhedonia in MDD
NCT07607938Phase 1Recruiting
- Sponsor
- NYU Langone Health
- Start
- Sep 2026
- Primary completion
- Aug 2030
- Countries
- 1
01
Overview
Phase 1, randomised trial of psilocybin in major depressive disorder (MDD) and anhedonia ((none)) (2 arms), sponsored by NYU Langone Health. Primary endpoints: Dimensional Anhedonia Rating Scale at 8 weeks and Fronto-Striatal Connectivity at 8 weeks. Started Sep 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)anhedonia ((none))
Beyond the preview
Go deeper on NCT07607938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07607938.